Linaclotide: Nursing Drug Guide, Severe Diarrhea & NCLEX Review
For irritable bowel syndrome with constipation and chronic constipation, linaclotide (LINZESS) works locally in the gut—but diarrhea is the dominant safety signal. Labeling directs nurses to suspend dosing and rehydrate when severe diarrhea occurs. Never give to children <2 years (boxed dehydration warning) or when mechanical GI obstruction is suspected.
LINZESS is contraindicated in patients <2 years because of risk of serious dehydration (deaths occurred in neonatal mice). In adults, diarrhea is the most common adverse reaction; severe diarrhea requires suspending the dose and rehydration per labeling. Postmarketing reports describe hospitalization with dizziness, syncope, hypotension, and electrolyte abnormalities. Also contraindicated with known or suspected mechanical gastrointestinal obstruction. Take on an empty stomach ≥30 minutes before a meal; do not crush or chew capsules.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before each dose, confirm age ≥2 years, no suspected obstruction, and the patient can take the capsule ≥30 minutes before breakfast on an empty stomach. Chart bowel pattern daily—severe or watery diarrhea means hold linaclotide, assess hydration and electrolytes, and notify prescriber/pharmacist. Verify capsule strength (72, 145, or 290 mcg) and that the capsule is swallowed whole, not crushed with food.
Most common brand names
Linaclotide is marketed in the United States as LINZESS. Capsule strengths are 72 mcg, 145 mcg, and 290 mcg (imprints FL 72, FL 145, FL 290 per DailyMed). Match the ordered strength to the indication: 290 mcg daily for adult IBS-C; 145 mcg daily (or 72 mcg for tolerability) for adult chronic idiopathic constipation.
Independent double-check is essential—strength mix-ups between 145 and 290 mcg change both efficacy and diarrhea risk.
Why we give it — Indications
Per FDA labeling (LINZESS / linaclotide), this guanylate cyclase-C agonist is indicated for:
| Use | Detail |
|---|---|
| IBS with constipation (IBS-C) | Adults and pediatric patients ≥7 years: 290 mcg daily (adults) or 145 mcg daily (pediatrics) |
| Chronic idiopathic constipation (CIC) | Adults only: 145 mcg daily, or 72 mcg daily based on presentation or tolerability |
| Functional constipation (FC) | Pediatric patients ≥6 years: 72 mcg daily |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Linaclotide is a guanylate cyclase-C (GC-C) agonist that acts locally in the intestine. It increases cyclic GMP, which raises fluid secretion into the intestinal lumen and accelerates transit. Systemic absorption is negligible at recommended doses—plasma concentrations of linaclotide and its active metabolite are below quantifiable limits in adults. The same secretory mechanism that relieves bowel habit symptoms explains why diarrhea is the primary dose-limiting toxicity—and why young children with elevated GC-C agonism are at risk for life-threatening dehydration.
Dosing overview
Dosing below reflects LINZESS (linaclotide) prescribing information (DailyMed, revised 11/2025). All doses are once daily on an empty stomach ≥30 minutes before a meal.
Renal / hepatic impairment: No dose adjustment expected—drug acts locally with negligible systemic exposure per label.
Missed dose: Skip the missed dose; take the next dose at the regular time. Do not take 2 doses at the same time.
Before you give it — Safety check
Pretreatment checks
- Confirm age ≥2 years (boxed warning—never administer to infants/toddlers <2 y)
- Verify indication and capsule strength (72 vs 145 vs 290 mcg) against the MAR
- Assess last bowel movements, stool consistency, hydration, orthostatic vitals, and oral intake
- Confirm patient can take dose ≥30 minutes before first meal on an empty stomach
- Perform medication reconciliation for duplicate laxatives or opposing antidiarrheals
Contraindications (labeling)
- Patients <2 years of age — risk of serious dehydration
- Known or suspected mechanical gastrointestinal obstruction
Drug interactions
| Drug / factor | Effect | Nursing action |
|---|---|---|
| Formal interaction studies | No drug-drug interaction studies conducted; negligible systemic exposure; no anticipated CYP or transporter interactions per label | Still reconcile bowel regimens clinically |
| Other laxatives / stimulants | Additive secretory effect—not studied as formal DDI | Clarify with pharmacist before stacking; increases diarrhea risk |
| Loperamide and antidiarrheals | Opposing therapy—may mask dehydration while constipation persists | Do not start without prescriber plan; report severe diarrhea first |
| Diuretics | Diarrhea plus diuresis increases hypokalemia / hyponatremia risk (postmarketing) | Trend basic metabolic panel when diarrhea develops |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Oral capsule: Take on an empty stomach at least 30 minutes before a meal, at approximately the same time each day. Swallow whole—do not crush or chew the capsule or beads.
- If swallowing is difficult, capsules may be opened and given in applesauce or water, or via NG/gastrostomy tube per full prescribing instructions—consume immediately; do not store mixtures
- When sprinkling on applesauce: do not chew beads; swallow entire mixture promptly
- Document time given relative to breakfast and any diarrhea that follows within 24–48 h of initiation
Administration errors—taking with food, crushing capsules, or doubling after a missed dose—can worsen abdominal pain and diarrhea without improving constipation control. Teach patients the empty-stomach rule and verify technique on teach-back.
Expected therapeutic response
- Increased bowel movement frequency and improved stool consistency in IBS-C and CIC over time—benefit may build across the first weeks
- Many patients report early abdominal pain, flatulence, or bloating that may lessen with continued therapy per labeling
- Diarrhea often begins within the first 2 weeks—distinguish expected mild loose stools from severe diarrhea requiring dose suspension
- Re-evaluate if diarrhea persists despite holding dose, or if dehydration signs appear—outcome surveillance is a nursing responsibility
Red flags — Stop and act
Hold linaclotide and escalate per protocol when:
- Severe or persistent watery diarrhea—labeling: suspend dosing and rehydrate
- Dizziness, syncope, or hypotension after diarrhea (postmarketing reports)
- Signs of dehydration—dry mucosa, poor intake, orthostatic vitals, decreased urine output
- Hypokalemia or hyponatremia on BMP after GI losses
- Acute worsening abdominal pain with distension or vomiting suggesting obstruction
- Any attempt to administer to a child <2 years—contraindicated; notify prescriber and pharmacy immediately
Adverse effects
Most common adverse reactions in adults with IBS-C or CIC (≥2% and greater than placebo): diarrhea, abdominal pain, flatulence, abdominal distension. In pediatric FC or IBS-C trials, diarrhea was the most common reaction (≥2%).
| Adverse effect | Context | Nursing response |
|---|---|---|
| Diarrhea | Most common; severe diarrhea ~2% on 145/290 mcg in adults; suspend dose and rehydrate if severe | Hold dose; I&O; trend electrolytes |
| Abdominal pain | Common early; may decrease with continued use | Differentiate from obstruction; notify if severe or persistent |
| Flatulence / distension | Frequent GI symptoms per trials | Teach expected vs red-flag pain pattern |
| Dehydration / electrolyte loss | Postmarketing: dizziness, syncope, hypotension, hypokalemia, hyponatremia with hospitalization | Orthostatic vitals; BMP; escalate severe cases |
| Dose reductions / discontinuation | Open-label trials: ~27–29% had dose reduced/suspended for GI adverse reactions, mostly diarrhea | Document prescriber communication when therapy adjusted |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Healthy-subject studies used single LINZESS doses up to 2897 mcg; the safety profile was consistent with the treated population, with diarrhea the most commonly reported reaction. No specific antidote is listed in the reviewed prescribing information.
Nursing actions
- Suspend linaclotide and provide rehydration per clinical judgment and prescriber direction
- Monitor vital signs, mental status, and BMP (sodium, potassium, BUN/creatinine)
- Supportive care for abdominal cramping and volume depletion
Contact local poison control or medical toxicology services per facility protocol for suspected overdose or severe dehydration. Use local emergency pathways for syncope, arrhythmia with electrolyte derangement, or inability to maintain oral fluids.
Look-alike / sound-alike and error prevention
- Linaclotide vs antidiarrheals—opposite bowel effects; wrong drug masks dehydration or worsens constipation
- LINZESS 72 vs 145 vs 290 mcg—independent double-check capsule strength to indication
- Brand LINZESS vs generic name—verify MAR after formulary switches
- Linaclotide vs lactulose / docusate—different classes; do not substitute without orders
- Crushed capsule with breakfast—administration error that increases diarrhea risk; teach empty-stomach timing
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Morning routine | Schedule med pass so dose is ≥30 min before breakfast—not with food |
| First 2 weeks | Diarrhea often starts early—pre-teach what “severe” means (watery, dizzy, unable to drink) |
| Capsule handling | Swallow whole; if opened for applesauce, do not chew beads |
| Pediatric safety | Triple-check age on pediatric units—never dispense to infants <2 y |
| Commonly missed | Patient feels “better” with diarrhea so continues taking with meals |
| Ask pharmacy when | Strength change, swallowing difficulty, or NG tube administration needed |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Children <2 years | Contraindicated—boxed warning for serious dehydration |
| Pediatrics ≥6–17 years | Approved doses differ from adults; severe diarrhea reported in trials—monitor closely |
| Older adults (≥65 y) | Insufficient trial numbers to determine different response; cautious dose selection per label |
| Diuretic or ACE inhibitor co-therapy | Higher risk when diarrhea causes electrolyte loss |
| Pregnancy | Negligible systemic absorption; insufficient human data on major birth defects/miscarriage—animal studies showed no embryo-fetal effects at high doses |
| Lactation | Not detected in breast milk in study; effects on milk production unknown—weigh breastfeeding benefits with clinical need |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Stool frequency and consistency (mild loose vs severe watery diarrhea)
- Vital signs—including orthostatic BP/HR when diarrhea or dizziness occurs
- Intake and output, mucous membranes, and weight trend
- BMP if severe diarrhea, syncope, or diuretic co-therapy (sodium, potassium)
Document
- Dose strength, time given relative to meals, and holds with prescriber notification
- Patient teaching on empty-stomach administration and swallow-whole rule
- Response after dose reduction or suspension—evaluate whether constipation symptoms return without harm
Patient teaching
- Take on an empty stomach at least 30 minutes before breakfast (or the same meal daily)
- Swallow the capsule whole—do not crush, chew, or break
- Report severe or watery diarrhea, dizziness, fainting, or inability to keep fluids down
- If a dose is missed, skip it—do not double the next dose
- Do not give this medicine to children under 2 years; keep out of reach of younger siblings
- Early gas or bloating may improve—persistent severe abdominal pain needs evaluation
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Patient is <2 years of age or MAR strength/indication mismatch
- Severe or persistent watery diarrhea—labeling: suspend dosing and rehydrate
- Signs of dehydration, orthostatic hypotension, syncope, or poor oral intake
- Suspected mechanical GI obstruction (pain, distension, vomiting)
- Cannot take dose ≥30 minutes before a meal on empty stomach as directed
- Wrong capsule strength (e.g., 290 mcg ordered for CIC when 145 mcg intended) until pharmacy clarifies
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Safe linaclotide practice centers on diarrhea surveillance, empty-stomach administration, and pediatric age verification—not assuming more bowel activity equals success.
1. Check-before-you-give protocol
- Right patient, drug, strength (mcg), route, time, and indication (IBS-C vs CIC)
- Age ≥2 years; no suspected obstruction
- Stool pattern and hydration status in last 24 h
- Meal timing—dose due only if ≥30 min before eating
2. High-alert and safety badge
Not an ISMP high-alert medication — boxed pediatric warning and severe diarrhea still high-stakesWrong age or strength, or continued dosing through severe diarrhea, can cause preventable dehydration and electrolyte crises.
3. Clinical workflow: hold and question rules
- Four watery stools since yesterday → hold today’s dose and notify before administration
- Patient took capsule with breakfast → teach and notify—do not silently continue error
- PRN antidiarrheal requested without prescriber plan → clarify bowel regimen with pharmacy
4. Critical teach-back questions
- “When do you take linaclotide relative to meals?” — Accept: at least 30 minutes before eating, on an empty stomach
- “What diarrhea should you report right away?” — Accept: severe or watery diarrhea, dizziness, or inability to keep fluids down
5. Care coordination
Pharmacist: Strength verification, swallowing alternatives (applesauce/NG), duplicate laxative reconciliation
Prescriber / GI: Persistent severe diarrhea, dose reduction to 72 mcg in CIC, or alternative therapy if dehydration recurs
🧠 Quick mental checklist
- Is the patient ≥2 years and obstruction-free?
- Is this the correct mcg strength for IBS-C vs CIC?
- Will the dose be given ≥30 minutes before food?
- Is diarrhea mild expected effect or severe hold-level toxicity?
- After a hold, are hydration and electrolytes improving on the next assessment?
Linaclotide NCLEX practice questions
Practice NCLEX-style clinical judgment practice for linaclotide using a tabbed case (MAR, labs, vitals, nursing notes), then priority action, cue recognition, trend interpretation, matrix urgency matching, clinical judgment, and documentation cloze—focused on severe diarrhea, dehydration, and empty-stomach administration.
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- Linaclotide (LINZESS) 290 mcg PO daily — 0730 due (AC breakfast)
- Hydrochlorothiazide 25 mg PO daily
- Docusate 100 mg PO BID PRN — last given 48 h ago
- No loperamide on MAR
- Na 134 mEq/L (was 139 mEq/L two days ago)
- K 3.1 mEq/L (was 3.8 mEq/L two days ago)
- BUN 22 mg/dL; creatinine 0.9 mg/dL
- BP 98/60 lying; 84/55 standing; HR 102
- Temp 36.9 °C; RR 18; SpO2 97% on room air
- Oral intake ~600 mL in 24 h; urine output decreased
- Day 5 of linaclotide; 6 watery stools in 12 h
- Patient reports dizziness when standing; took capsule with breakfast yesterday and today
- Pharmacy verified 290 mcg for IBS-C indication
Answer key & rationale
Frequently asked questions
When should nurses hold linaclotide?
Hold and contact the prescriber or pharmacist when the patient is less than 2 years of age, has known or suspected mechanical gastrointestinal obstruction, develops severe diarrhea, shows dehydration or orthostatic hypotension, or cannot take the capsule on an empty stomach at least 30 minutes before a meal as directed.
What is the main adverse effect nurses must monitor with linaclotide?
Diarrhea is the most common adverse reaction per LINZESS labeling. Severe diarrhea occurred in about 2 percent of adults on 145 or 290 mcg daily. If severe diarrhea occurs, suspend dosing and rehydrate the patient. Postmarketing reports include hospitalization for dehydration with electrolyte abnormalities.
How should linaclotide be administered?
Take on an empty stomach at least 30 minutes before a meal at approximately the same time each day. Swallow the capsule whole; do not crush or chew. If a dose is missed, skip it and take the next dose at the regular time—do not double.
Is linaclotide safe in pregnancy or breastfeeding?
Systemic exposure is negligible; available human pregnancy data are insufficient to inform drug-associated risk. Linaclotide was not detected in breast milk in a small study; effects on milk production are not known—consider benefits of breastfeeding with clinical need for LINZESS.
Why is linaclotide contraindicated in children under 2 years?
LINZESS carries a boxed warning for risk of serious dehydration in pediatric patients less than 2 years of age. In neonatal mice, a clinically relevant oral dose caused deaths due to dehydration from age-dependent GC-C agonism.
What is the management of linaclotide overdose?
Single doses up to 2897 mcg in healthy subjects produced diarrhea as the most common reaction. No specific antidote is listed. Management is supportive: suspend dosing, rehydrate, monitor electrolytes, and contact local poison control or medical toxicology services per facility protocol.
References
- U.S. National Library of Medicine. LINZESS (linaclotide) capsules — Full prescribing information. DailyMed. Revised 11/2025.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09beda19-56d6-4a56-afdc-9a77b70b2ef3
- U.S. Food and Drug Administration. LINZESS (linaclotide) capsules — Prescribing information (NDA 202811). Label version 11/2025.https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/202811s022lbl.pdf
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.